Company profile for ProMIS Neurosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF).ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerat...
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF).ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/10/3203075/0/en/ProMIS-Neurosciences-Announces-New-Peer-Reviewed-Publication-Highlighting-Selective-Targeting-of-Toxic-Oligomers-for-Potential-Clinical-Benefit-and-Reduced-ARIA-Risk.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3196921/0/en/ProMIS-Neurosciences-Announces-New-Peer-Reviewed-Publication-Showing-Plasma-pTau-as-a-Predictive-Early-Endpoint-in-Alzheimer-s-trials-Supporting-its-Ongoing-Phase-1b-PRECISE-AD-tri.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3196854/0/en/ProMIS-Neurosciences-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193417/0/en/ProMIS-Neurosciences-Announces-Reverse-Stock-Split.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186059/0/en/ProMIS-Neurosciences-Announces-Third-Quarter-2025-Financial-Results-Corporate-Highlights.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179794/0/en/ProMIS-Neurosciences-to-Participate-in-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference.html

GLOBENEWSWIRE
03 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty